Cardinal Health CAH
Healthcare · Medical - Distribution · Synthos Deep Dive · 2026-07-03
The Overview
Cardinal Health is a middleman. It buys medicines and medical supplies from the companies that make them and delivers them to hospitals, pharmacies, and now people's homes. It is one of only three big players in the US that do this at scale, so it is genuinely essential plumbing for healthcare — but it is a volume, not a margin, business: on every $100 of goods it moves, it keeps under $4 of gross profit and well under $1 of actual net profit.
The good news: management has run the company well lately. Profits per share are set to jump about 30% this year, debt is down, and they are buying back stock. The stock noticed — it is up about 45% in a year and sits at its highest price ever.
Our verdict is Watch, not Buy. The company is fine and the price is not crazy, but the stock has already climbed a lot and now trades near the top of what it is worth. Better to wait for a dip than to chase it at the high.
Here is what our three scores mean in everyday terms:
- Downside Risk 4/10 (fairly low). The stock is steady (it doesn't swing much) and cheap on next year's profits — but the business runs on wafer-thin margins and still carries a legal/opioid tail, so it isn't bulletproof.
- Growth Quality 5/10 (middle of the road). Profits are growing, but a big chunk of that comes from buybacks, taxes, and cost-cutting rather than from selling a lot more.
- Exponential Potential 2/10 (low). This is a slow, steady utility-like business. Don't expect it to double quickly — that is not what it is.
The one big worry: the stock has already priced in the good news. Buying at a fresh all-time high after a 45% run leaves little cushion if generic-drug prices deflate faster than expected or tariffs squeeze the medical-products arm.
Putting a number on it: our fair-value estimate is $256 against a current price of $234.55 — real upside if our numbers are right.
Our summary metrics
Low beta (0.49) & cheap on forward EPS, but razor-thin margins, negative book equity, 3.0× adjusted leverage & opioid/secular tail.
~14% forward EPS CAGR is real but engineered (buybacks, tax, mix) — organic revenue only ~8%, gross margin 3.7%.
Low-margin drug distributor; decelerating and no TAM to multibag — a compounder, not an exponential.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Low-margin drug distributor; decelerating and no TAM to multibag — a compounder, not an exponential.
“McKesson and Cardinal Health trade below market multiple yet keep producing significant price returns; as momentum names they haven't unwound because they make money and are reasonably priced.”
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $253 (high $275 / low $235; 18 Buy · 15 Hold · 0 Sell) — context, not our anchor |
| Valuation | 36× trailing GAAP EPS · ~22× FY26E · ~20× FY27E · ~13× FY30E non-GAAP · EV/EBITDA 20× · EV/Sales 0.24× |
| Technicals | Extended — $239 sits at the 52-wk high, above 50/200-DMA, RSI 77 (overbought), +45% 12-mo (SPY +21%) |
| Conviction | Low — 0 expert voices in the Synthos KB; the verdict rests entirely on the numbers |
| Position sizing | Value/defensive satellite, ≤2–3% — and only on a pullback, not at the high |
What the experts actually said 1 traceable claims on CAH · showing the highest-conviction voices
“McKesson and Cardinal Health trade below market multiple yet keep producing significant price returns; as momentum names they haven't unwound because they make money and are reasonably priced.”
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $234.55, 1% above the 50-day average ($233), 9% above the 200-day average ($215) — an uptrend. 2% below the 52-week high of $240, 59% above the 52-week low of $147.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $234.55 is currently inside the band (band $229–$241).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 52.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.17, negative momentum.
Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago
Solid = CAH · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Cardinal Health (NYSE: CAH), founded 1979, headquartered in Dublin, Ohio, is one of the "big three" US healthcare distributors (with McKesson and Cencora). It is the essential logistics layer of American healthcare: it buys branded, generic, and specialty pharmaceuticals and medical/surgical supplies and distributes them to hospitals, pharmacies, clinics, surgery centers, labs, physician practices, and increasingly patients at home. Fiscal year ends June 30.
The company reports on a restructured segment map as of FY26:
- Pharmaceutical & Specialty Solutions — the engine. Distribution of brand/generic/specialty drugs plus specialty-provider services. Q3 FY26 revenue $56.1B (+11%), segment profit $784M (+18%).
- Global Medical Products & Distribution (GMPD) — Cardinal-branded and national-brand medical/surgical products. Q3 FY26 revenue $3.1B (flat), segment profit $25M (−36%, hurt by tariffs). The perennial problem child.
- Other — three growth businesses: at-Home Solutions, Nuclear & Precision Health Solutions, and OptiFreight Logistics. Q3 FY26 revenue $1.7B (+31%), segment profit $179M (+34%). Small but the fastest-growing, higher-margin piece.
Revenue mix (FY2025, from filings):
- By segment: Pharmaceutical ~$204.6B (~92%) · GMPD ~$12.6B (~5.7%) · Other ~$5.4B (~2.4%). The economics are lopsided: >90% of revenue is the ultra-thin-margin pharma-distribution flow.
- By geography: United States $220.99B (~99.3%) · Non-US $1.67B. This is a domestic US business — a concentration that is both a simplicity strength and a US-drug-policy/tariff risk (§11).
The strategic story is a margin-mix upgrade: lean into specialty, nuclear/radiopharmaceuticals (a real growth vector — see the Actinium-225 capacity expansion), at-home, and logistics, while fixing or shrinking the low-return GMPD medical-products arm.
2. The expert thesis — why the panel is bullish (traceable)
There is no expert coverage of Cardinal Health in the Synthos knowledge base. total_claims = 0; there are zero net-bullish (or net-bearish) voices, and therefore no claim_id values to cite. We will not manufacture conviction we do not have.
This verdict is entirely fundamentals- and quant-driven. Everything below is derived from the reported financials, live analyst estimates (FMP), management's own SEC-filed guidance (half-weighted, §9), and our own scenario model. Treat the absence of an expert panel as a lower-conviction signal in its own right: this is not a name our tracked, skill-weighted voices are talking about. Where the Street has a view, we cite it as context (18 Buy / 15 Hold, consensus target $253) — not as our anchor.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 4 · Low-Moderate | Beta 0.49 and ~22× forward / 13× FY30E EPS make it defensive and cheap; but 3.7% gross margin, <1% net margin, negative book equity, ~3.0× adjusted leverage and an opioid/secular tail cap how safe it really is. |
| Growth Quality | 5 · Moderate | ~14% forward EPS CAGR and rising segment profit are real, but organic revenue growth is only ~8% and a large slice of EPS growth is buybacks + a falling tax rate + mix, not volume. ROIC ~12% is decent for a distributor, not elite. |
| Exponential Potential | 2 · Low | A thin-margin distribution utility. Growth is decelerating, and a $222B revenue base against a low-single-digit margin leaves no TAM to multibag. Own it for yield + steady compounding, never for a moonshot. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them. All EPS figures are non-GAAP, matching how management and the Street frame the stock.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Specialty/nuclear/at-home mix keeps lifting margins; GMPD turns; generics deflation stays benign. FY28E non-GAAP EPS beats to ~$15 (vs ~$13.5 cons); the market keeps paying up for the re-rated story at ~22×. | ~$330 (+38%) |
| Base (our anchor) | Guidance roughly holds — FY26 EPS ~$10.75, compounding to FY28E ~$13.5; a steady mid-teens-EPS-grower earns a ~19× multiple (a modest premium to its history as the mix improves). | ~$256 (+7%) |
| Bear | Generic price deflation accelerates, tariffs keep hitting GMPD, or a large customer (~30%+ from top accounts) renegotiates; FY28E EPS stalls near ~$11 and the multiple de-rates to ~15× as the re-rating unwinds. | ~$165 (−31%) |
Synthos fair value = the base case, ~$256 (+7%), with the full $165–$330 span as the honest range. This anchor sits essentially on top of the Street's $253 consensus — a rare case where our independent model and the sell-side agree the stock is roughly fairly valued after its run. That agreement, plus the absence of any expert-panel edge, is exactly why the verdict is Watch, not Buy: at +7% to base with a fresh 52-week high and RSI 77, the risk/reward is balanced, not compelling. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable, steady returns) from exponentials (accelerating, multi-baggers-from-here). CAH is neither an exponential nor even a fast compounder — it is a defensive value re-rating that has largely played out:
- Forward growth: revenue CAGR FY25→FY30E only ~8.8% ($222.6B → $339B); non-GAAP EPS CAGR FY26→FY30E ~13.6% ($10.77 → $17.92). The EPS line grows faster than revenue because of buybacks, a falling tax rate (guided ~19% for FY26), and margin mix — not because the core is accelerating.
- Acceleration (the 2nd derivative) is negative: the big jump is FY25→FY26 (non-GAAP EPS +30%, off a depressed base and a tax/leverage reset). After that, EPS growth decelerates — FY26→FY27 ~+12%, then low-teens tapering toward high-single-digits. The turnaround snap-back is a one-time event, not a new growth curve.
- Room to run: essentially none in the multibag sense. On a $222B revenue base at a ~3.7% gross and <1% net margin, there is no addressable-market lever that turns this into a 5×. A 5× from $56B implies a ~$280B distributor — larger than the entire US drug-distribution profit pool can support at these margins.
- Reinvestment runway: modest and disciplined — capex is tiny (~$550M/yr, 0.25% of revenue), the model is negative-working-capital (cash-conversion cycle −10 days), and free cash flow (~$1.9B FY25, guided $3.3–3.7B adjusted FY26) mostly funds buybacks and the dividend rather than transformational reinvestment.
Exponential Potential: Low (2/10). Own CAH — if at all — for a mid-single-digit dividend-plus-buyback compounding profile and defensiveness, never for a fast multibagger. A small, accelerating specialty-services name with these returns on capital would score far higher; a $56B distributor of a maturing, deflating drug flow does not.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 (June 2025) $222.6B, −1.9% (FY24 $226.8B; the dip reflects a large customer contract expiration). TTM revenue is re-accelerating: quarterly $54.9B (Q3'25) → $60.2B → $64.0B → $65.4B → $60.9B (Q3'26, +11% YoY). Enormous top line, but that is the point about margins below.
- Margins (the whole story): gross 3.7% TTM, EBITDA ~1.2%, net ~0.6%. This is a logistics spread business — pennies on huge volume. The improvement is at the segment-profit line (Pharma +18%, Other +34%), which is what matters.
- GAAP vs non-GAAP gap: GAAP FY25 EPS was $6.45 (net income $1.56B); Q3 FY26 GAAP EPS was $1.69 (dinged by a $184M Navista goodwill impairment) versus non-GAAP $3.17 (+35%). The stock trades on the non-GAAP number — fair, given the impairments and amortization, but the gap is real and worth watching.
- Earnings power: management guides FY26 non-GAAP diluted EPS to $10.70–$10.80 (+30–31%) — the core bull fact.
- Cash flow: FY25 operating CF $2.40B, capex −$0.55B, FCF $1.85B; FY26 adjusted FCF guided $3.3–3.7B. Capex-light and negative-working-capital, so FCF conversion is strong when working capital cooperates.
- Balance sheet (the caveat): total debt ~$9.3B, net debt ~$5.5B, net-debt/EBITDA ~1.65× (FMP TTM) / 3.0× on management's Moody's-adjusted definition (their targeted 2.75–3.25× range). Shareholders' equity is negative (−$2.8B) — a function of years of buybacks and past impairments, not distress, but it makes book-value and ROE metrics meaningless (ROE screens as −56%; ignore it — use ROIC ~12% and ROCE ~16% instead).
6. Valuation — priced in or room?
On trailing GAAP EPS ($6.63 TTM) the stock looks expensive at ~36×, but that is the wrong lens — the market prices CAH on non-GAAP earnings, where it is cheap-to-fair: ~22× FY26E ($10.75), ~20× FY27E ($12.01), ~18× FY28E ($13.5), ~13× FY30E ($17.92). EV/EBITDA is ~20× and EV/Sales a rounding-error 0.24× (as expected for a distributor). The free-cash-flow yield is a healthy ~7.8%, and the dividend yields ~0.9% with a low ~31% payout — plenty of buyback firepower.
The honest read: the multiple has already re-rated from distressed (~10× a couple of years ago) to a normalized ~20× as the turnaround took hold. At today's ~22× forward, you are no longer buying a cheap turnaround — you are paying a fair price for a proven one. Our base-case FV of ~$256 (+7%) essentially matches the Street's $253 consensus (high $275 / low $235), which is unusual and telling: independent model and sell-side agree there is little discount left. FMP's quantitative letter rating is C+ (overall score 2/5), reflecting the weak balance-sheet and margin optics. Not a value screen bargain anymore; a fairly-priced, well-run defensive — hence Watch.
7. Technicals (computed from EOD price history)
- Trend: up, and extended. $239 sits above the 50-DMA ($207.57) and 200-DMA ($201.04), and the 50 is above the 200 (golden-cross posture). MACD +9.2 (positive).
- Location: at the 52-week high ($238.94) — 0% off the peak, +63.6% off the 52-week low ($146.04). Zero drawdown from peak means there is no built-in margin of safety on the chart.
- Momentum: RSI(14) 76.9 — overbought (>70). This is the single clearest technical caution: buying here is buying a stretched entry.
- Relative strength: CAH +45.3% 12-mo vs SPY +20.6% and QQQ +30.3%; +12.7% 3-mo (vs SPY +13.7%, i.e. lagging the market over 3 months even as it hits highs). Twelve-month leadership, but the near-term relative-strength edge has faded.
- Read: technicals say don't chase. A defensive name at a fresh high with RSI 77 is exactly the setup where waiting for a pullback toward the rising 50-DMA (~$208) offers a materially better entry. No technical reason to buy today.
8. Moat & competitive position
Cardinal's moat is scale and oligopoly structure, not brand or technology. US pharmaceutical distribution is a three-firm oligopoly — Cardinal Health, McKesson, and Cencora move the overwhelming majority of the nation's drug volume. The barriers are real: national distribution infrastructure, razor-thin margins that deter new entrants, deep manufacturer and pharmacy relationships, and negative-working-capital economics that reward incumbency. But it is a low-margin moat — pricing power flows to manufacturers and large buyers (the biggest customers are enormous pharmacy chains that can and do renegotiate hard), and the secular threat is disintermediation (Amazon Pharmacy, direct-to-manufacturer models, Mark Cuban-style cost-plus).
Peer set (FMP-supplied; market cap): the closest true comp is Cencora (COR) $58B — the direct distribution peer. The rest of the FMP list are medtech/life-science/health-IT names, not distribution comps: Becton Dickinson $57B, argenx $58B, Edwards Lifesciences $54B, Haleon $43B, Agilent $37B, IQVIA $35B, Veeva $31B, ResMed $30B, Bruker $9B. Against Cencora specifically, Cardinal trades at a similar-to-modest-discount multiple with a comparable margin profile; McKesson (not in this list) is the scale leader. CAH is the mid-pack distributor executing a credible catch-up.
9. Management, capital allocation & guidance
- Capital allocation: disciplined and shareholder-friendly. FY26 to date: $1.0B of buybacks (including a $250M accelerated repurchase), a $100M term-loan prepayment ahead of schedule, leverage cut to 3.0× (within the 2.75–3.25× target, investment-grade maintained), plus a growing dividend (~$0.51/qtr, ~31% payout). Capex is minimal. This is textbook late-cycle-distributor capital return, appropriate for the returns on capital.
- Insider activity: a normal mix of Rule-10b5-1 sales and tax-withholding (F-InKind) events in early 2026 (CFO Aaron Alt, CIO Michelle Greene, a director) at $220–$230, plus routine director awards. Nothing that clusters into an alarming discretionary-selling signal, but also no conviction buying — neutral.
- Management's own guidance (half-weighted — they talk their book): the SEC 8-K (Item 2.02) earnings release dated 2026-04-30 is a real Q3 FY26 release and management raised and narrowed FY26 non-GAAP EPS guidance to $10.70–$10.80 (+30–31%), driven by Pharmaceutical & Specialty segment profit growth of 22–23% and Other segment growth of 36–38%, a lower non-GAAP tax rate (~19%), ~237M diluted shares, and adjusted FCF raised to $3.3–3.7B. CEO Jason Hollar framed it as "durability and resilience… long-term value creation." We weight this at half — it is management's self-interested framing — but it is specific, twice-raised, and corroborated by the reported segment numbers, so it earns some credit.
10. Catalysts & what to watch
- Next earnings: 2026-08-11 (Q4 FY26; Street EPS $2.41, revenue ~$65.2B). The key lines: full-year non-GAAP EPS landing vs the $10.70–$10.80 guide, and initial FY27 guidance — the market will judge whether the +30% snap-back gives way to a durable low-teens grower.
- Generic drug deflation / brand inflation mix: the swing factor for Pharmaceutical segment profit — benign deflation has been a tailwind; an acceleration is the core bear risk.
- GMPD turnaround & tariffs: medical-products profit fell 36% on tariffs; watch for stabilization or further erosion.
- Growth businesses: at-Home (Advanced Diabetes Supply acquisition), Nuclear/radiopharma (the Actinium-225 capacity build), and OptiFreight — the higher-margin mix-shift story.
- Capital return: continued buybacks and leverage staying inside 2.75–3.25×.
Thesis tripwires (what would change the call): initial FY27 EPS guidance materially below low-teens growth; a re-acceleration of generic price deflation; a large-customer contract loss/renegotiation; or the opioid/legal tail re-opening. Any of these flips Watch toward Avoid; a pullback to the 50-DMA with the fundamentals intact flips it toward Buy — Tactical.
11. Key risks
- The re-rating is largely done (valuation): at a fresh 52-week high, RSI 77, ~22× forward and +7% to our base FV, the risk/reward is balanced — buying here has little cushion.
- Wafer-thin margins: a 3.7% gross / <1% net margin means small deflation, tariff, or mix shocks swing profit meaningfully.
- Customer concentration: the big-three distributors serve enormous pharmacy chains that renegotiate aggressively; a major contract shift (as in FY25) dents revenue and profit.
- Negative book equity / leverage optics: −$2.8B equity and 3.0× adjusted leverage make the balance sheet screen poorly (FMP rates it C+) even if it is serviceable.
- Secular disintermediation: Amazon Pharmacy, cost-plus/direct-to-manufacturer models, and PBM/pricing-policy reform are slow-burn threats to the middleman.
- Opioid/legal tail: the distribution industry carries residual opioid-settlement obligations and reputational/legal risk.
- No expert-panel corroboration: zero Synthos KB coverage means no independent conviction beyond the quant/fundamental case — a lower-confidence signal by construction.
12. Verdict, position sizing & monitoring
Watch. Cardinal Health is a genuinely improved business — a well-run drug-distribution oligopolist that has cut leverage, grown segment profit double-digits, guided non-GAAP EPS +30% to ~$10.75, and returned $1B to shareholders. But the market has already paid for the turnaround: the stock is up ~45% in a year, sits at its all-time high with an overbought RSI of 77, and trades at ~22× forward earnings where our independent base-case fair value (~$256) and the Street's ($253) both land within a few percent of today's price. There is no expert-panel edge in the Synthos KB to lean on, and no margin-of-safety left on the chart or the multiple. That combination is a textbook Watch, not a Buy.
- Sizing: if owned at all, a value/defensive satellite of ≤2–3%, and preferably initiated on a pullback toward the rising 50-DMA (~$208) rather than at the high. This is a "buy the dip in a quality utility," not a "chase the breakout" name.
- Monitoring: re-underwrite on the FY27 guide at the 2026-08-11 print and on the tripwires in §10; formal re-score each earnings print. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $238.94.
- Single biggest risk: the good news is already in the price — a fast re-rating to a fresh high leaves little cushion if generic deflation or tariffs surprise to the downside.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — no expert coverage in the Synthos KB, so no
claim_ids are cited; this call is fundamentals- and quant-driven and labeled as such. Fabricated conviction is structurally impossible (claim-ID reconciliation), and we explicitly decline to invent a panel where none exists. - Data as-of: fundamentals 2026-03-31 (Q3 FY26) · estimates & prices 2026-07-02/03 · management guidance from the SEC 8-K dated 2026-04-30. Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates.
- Management caveat: CAH management's raised FY26 guidance is management's own book, half-weighted by design; it is corroborated by reported segment results.
- Non-GAAP note: valuation and EPS growth are framed on management/Street non-GAAP EPS; the GAAP-to-non-GAAP gap (impairments, amortization) is real and disclosed in §5.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").